Merck Shares Enpatoran SLE Efficacy & Safety Data at EULAR 2025
Merck Highlights Positive Enpatoran Phase 2 WILLOW Study Data in SLE at EULAR 2025 Merck, a leading science and technology company, today presented new and detailed results from its Phase…
GSK Licenses Shigella Vaccine Candidate to Bharat Biotech
GSK Licenses Shigella Vaccine Candidate to Bharat Biotech in Push for Global Health Equity GSK today announced a significant step forward in the battle against Shigella a leading cause of…
Bristol Myers Squibb Highlights Targeted Protein Degradation Data, Including CELMoD Agents, at EHA 2025
Bristol Myers Squibb Highlights Targeted Protein Degradation Advances, Including CELMoD Agents and BCL6 Ligand-Directed Degrader, at EHA 2025 in Milan, Italy Bristol Myers Squibb today revealed new and updated data…
Rilzabrutinib Cuts Flares in IgG4-Related Disease; Fast Track Granted in US
EULAR 2025: Rilzabrutinib Shows Promise in IgG4-Related Disease — Reduction in Flares and Disease Activity Rilzabrutinib, a Bruton’s tyrosine kinase (BTK) inhibitor currently in clinical development, demonstrated a significant and…
Novartis Fabhalta Boosts Hemoglobin in PNH Patients
Novartis’ Fabhalta Shows Meaningful Hemoglobin Improvement in PNH Patients, Reinforcing Benefit of Oral Monotherapy Novartis recently announced positive results from its APPULSE-PNH study — a Phase IIIB trial evaluating Fabhalta®…
Merck Animal Health Gets EU CVMP Positive Opinion for NUMELVI Tablets for Dogs
Merck Animal Health Wins Positive EU CVMP Opinion for NUMELVI (atinvicitinib) Tablets for Dogs Merck Animal Health, a division of Merck & Co known as MSD Animal Health outside the…
Bleximenib Shows Promise with Venetoclax and Azacitidine in AML
Bleximenib Shows Promise in AML When Combined with Venetoclax and Azacitidine, According to Johnson & Johnson’s Phase 1b Data Presented at EHA 2025 Johnson & Johnson today presented new and…
First Patient Dosed in Phase 3 REVEAL Trial of ION582 for Angelman Syndrome
Ionis Begins Pivotal Phase 3 REVEAL Study of ION582 in Angelman Syndrome, Dosing First Patient in Global Trial Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) has announced the dosing of the first…
Parliamentarians Gather for Annual World Health Assembly
Global Parliamentarians Take the Stage at WHA78: A New Chapter in Health Governance The Seventy-eighth World Health Assembly (WHA78), held in Geneva in 2025, emerged as a landmark moment in…
FDA Approves Tablet Form of BeOne’s BRUKINSA® for All Indications
FDA Approves Tablet Formulation of BeOne’s BRUKINSA® for All Approved Indications, Offering Greater Convenience for Patients with B-cell Cancers BeOne Medicines Ltd. a global oncology-focused biopharmaceutical company, has received a…
argenx Unveils Positive Efgartigimod Phase 2 Data in Myositis and Sjogren’s at EULAR 2025
argenx Unveils Positive Phase 2 Results for Efgartigimod in Myositis and Sjogren’s Disease at EULAR 2025 argenx SE a global immunology company dedicated to advancing treatments for severe autoimmune diseases,…
Bayer, Broad Institute Extend Cardiovascular Drug Research Pact
Bayer and Broad Institute Extend Landmark Collaboration to Advance Cardiovascular Genomics and Precision Medicine In a bold continuation of a decade-long scientific alliance, Bayer and the Broad Institute of MIT…